Meclofenoxate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Meclofenoxate
Centrophenoxine.svg
Systematic (IUPAC) name
2-Dimethylaminoethyl (4-chlorophenoxy)acetate
Clinical data
AHFS/Drugs.com International Drug Names
Legal status ?
Identifiers
CAS number 51-68-3 YesY
ATC code N06BX01
PubChem CID 4039
ChemSpider 3899
UNII C76QQ2I0RG YesY
KEGG D00993 YesY
Chemical data
Formula C12H16ClNO3 
Mol. mass 257.713
 YesY (what is this?)  (verify)

Meclofenoxate (Lucidril), also known as centrophenoxine, is a drug used to treat the symptoms of senile dementia and Alzheimer's disease. It is an ester of dimethylethanolamine (DMAE) and 4-chlorophenoxyacetic acid (pCPA). DMAE is a natural substance, found especially in fish. pCPA is a synthetic compound that resembles a variety of plant hormones called auxins.

In elderly patients, it has been clinically shown to improve memory, have a mentally stimulating effect, and improve general cognition.[1] Meclofenoxate also increases cellular membrane phospholipids.[citation needed]

It is also used off-label as a nootropic, often combined with a racetam drug such as piracetam.[citation needed]

Side effects and contraindications[edit]

Meclofenoxate is generally considered safe. However possible side effects may include nausea or mild dizziness. People with severely high blood pressure or convulsive disorders such as epilepsy should avoid meclofenoxate.[2][unreliable source?] Large doses may cause tight jaw clenching.

See also[edit]

References[edit]

  1. ^ Marcer, D; Hopkins, SM (1977). "The differential effects of meclofenoxate on memory loss in the elderly". Age and ageing 6 (2): 123–31. doi:10.1093/ageing/6.2.123. PMID 329662. 
  2. ^ Centrophenoxine Page @ The American Academy of Anti-Aging Medicine